AGP Executive Report

Trade & Pharma Ties: India’s Commerce Minister Piyush Goyal has started a two-day Switzerland visit in Berne to push implementation of the India–EFTA Trade and Economic Partnership Agreement (TEPA), including talks with Swiss President Guy Parmelin, state officials, and leaders from the Swiss pharmaceutical and biotech sector. Local Relevance for Liechtenstein: Because TEPA covers the EFTA group that includes Liechtenstein, the focus on “operational issues” and smoother trade and investment could directly shape how health-related goods and services move across the region. EU Pressure on Mobility: A Swiss referendum on a population cap is raising alarm in Brussels, with concerns it could strain free movement rules that underpin wider EU–EFTA cooperation. Health Access Abroad: A UK travel warning highlights that many people still lack a GHIC, which can help cover state-provided medical care in Europe at local cost—an issue that matters for Liechtenstein residents traveling nearby. New Cell Therapy Deal: Medexus says it secured exclusive Canadian rights for UM171 cell therapy (Zemcelpro®) after Europe’s conditional authorization, signaling continued momentum in advanced blood-cancer treatments.

Trade & Pharma Ties: India’s Commerce Minister Piyush Goyal will visit Switzerland (Berne, June 12–13) to push the India–EFTA Trade and Economic Partnership Agreement (TEPA) rollout, including talks with Swiss officials and leaders of the Swiss pharmaceutical industry—an effort that also directly involves Liechtenstein as part of the EFTA group. Health & Access Abroad: A UK travel health warning says nearly half of Brits lack a GHIC, which can help cover state-provided medical care in Europe at local cost—urging travellers to get it before departure and still keep travel insurance. EU Migration Pressure: Switzerland’s upcoming vote on a population cap could strain EU relations, with Brussels stressing that free movement is central to the relationship. Medical Innovation: Medexus says Europe’s conditional approval for a cell therapy (Zemcelpro®/dorocubicel) is now tied to a Canada license and supply deal, with commercialization expected from 2028. Liechtenstein in the News: A piece on Liechtenstein highlights how the principality is leaning on regulation and cross-border access to grow its fintech ambitions despite its small size. Science & Health Research: A new space life sciences experiment launched from Sweden includes a partnership with Switzerland and Liechtenstein, studying how human immune cells respond to gravity changes.

India–EFTA Trade Push: Commerce minister Piyush Goyal is set to visit Switzerland next week to speed up the India–EFTA TEPA rollout, with talks in Berne and meetings planned with Swiss officials and the pharmaceutical industry to iron out implementation issues and expand trade and investment. Liechtenstein Fintech Focus: A new look at Liechtenstein’s 2026 strategy highlights how the tiny principality is leaning on regulation, cross-border access, and digital development to punch above its weight in global finance. Space & Health Research Link: Nevis launched the Caribbean’s first space life sciences experiment, partnering with the University of Zurich and the Centre for Space and Aviation Switzerland and Liechtenstein, aiming to study how gravity changes affect human immune cells—work that could inform health during long-duration missions. Sports & Wellness Adjacent: Liechtenstein was among teams playing friendlies recently, with Cyprus beating Liechtenstein 2-0 in one match. Travel Health Reminder: A UK-focused warning urges travellers to get a GHIC before trips, noting many people risk higher out-of-pocket medical costs abroad if they’re missing the card.

Sports & Health Travel: With the 2026 World Cup kicking off in 48 hours, a UK travel-insurance warning is getting attention: almost half of Brits risk costly medical bills abroad by not having a GHIC (Global Health Insurance Card), which can help cover state-provided care in Europe at local cost—though it doesn’t replace travel insurance. Pharma & Bone Health: CinnaGen says it has become the first Iranian pharma company to win EU approval for its osteoporosis medicine teriparatide (Zandoriah), following EMA review under EU biosimilar rules. Liechtenstein in the Mix (Sports Governance): Liechtenstein’s Alexander Ospelt is in the running for FIS president, as Johan Eliasch argues centralising ski commercial rights has boosted revenues and could raise athlete earnings. Local Wellness & Community: In Virginia, U.S. Rep. Donald Beyer returned to his district for a community potluck after a court restored the prior map—an example of how local civic life keeps moving even amid political shifts. Science & Human Health: Nevis launched the Caribbean’s first space life sciences experiment, studying how gravity changes affect human immune cells, with collaboration involving the University of Zurich and CSA Switzerland and Liechtenstein.

Travel Health Costs: A UK finance expert warns nearly half of Brits could face costly medical bills abroad because they don’t have a GHIC (Global Health Insurance Card), which can help cover state healthcare in Europe at local cost—though it doesn’t replace travel insurance. Pharma & Osteoporosis: CinnaGen became the first Iranian pharma firm to get EU approval for its osteoporosis medicine teriparatide (Zandoriah), following EMA review under EU biosimilar rules. Liechtenstein in Sports: In international friendlies, Cyprus beat Liechtenstein 2-0, adding to the week’s match results. Pet Health Tech: Fi, maker of AI GPS pet wearables, expanded coverage to 38 countries, including Switzerland and Liechtenstein, aiming to give owners health insights and tracking while traveling. Health Research in Space: Nevis launched the Caribbean’s first space life sciences experiment, studying how gravity changes affect human immune cells—developed with the University of Zurich and the Centre for Space and Aviation Switzerland and Liechtenstein.

Travel Health Costs: A UK finance expert warns that almost half of Brits risk expensive medical bills abroad because they skip the free GHIC, which can unlock state-provided care in Europe (at local cost or free) for emergencies and some pre-existing conditions—though it doesn’t replace travel insurance. Liechtenstein in the Region: A Swiss trade deal that cut tariffs from 39% to 15% is also tied to Liechtenstein via the customs union, with major pharma investment flows highlighted by Roche and Novartis. Space & Human Health Research: Nevis launched the Caribbean’s first space life sciences experiment on May 31, studying how microgravity and hypergravity affect human immune cells—built with the University of Zurich and the Centre for Space and Aviation Switzerland and Liechtenstein. Pet Health Tech: Fi expanded its AI-powered GPS pet wearables to 38 countries, including Switzerland and Liechtenstein, aiming to pair health insights with reliable tracking for owners who travel. Community & Wellness: Two cyclists plan a Rhine Cycle Route fundraiser for a baby-loss bereavement suite at Southmead Hospital, linking physical activity with support for families.

Travel Health Access: A UK travel warning is going around: nearly half of Brits don’t have a GHIC, risking out-of-pocket medical bills abroad. The Global Health Insurance Card can help cover state-provided care in Europe (often at local cost or free), but it doesn’t replace travel insurance. Pharma in Europe: The European Commission has approved CinnaGen’s teriparatide (Zandoriah) for osteoporosis, marking a first for an Iranian company in the EU. Cancer Treatment Update: Europe has also approved Opdivo (nivolumab) plus AVD chemotherapy as the first immunotherapy-based regimen for newly diagnosed advanced classical Hodgkin lymphoma in patients aged 12+. Research & Health in Space: Nevis launched the Caribbean’s first space life sciences experiment, studying how microgravity and hypergravity affect human immune cells—aimed at improving health knowledge for long-duration missions. Liechtenstein Link: A Swiss trade deal that includes Liechtenstein is driving major pharma investment into the US, with Roche and Novartis leading large commitments.

Pharma Investment & Access: Swiss firms are accelerating US spending after a trade deal cut tariffs on Swiss goods from 39% to 15%, with Roche pledging $50B and Novartis $23B—an update that also matters for Liechtenstein via the customs union. Cancer Care Update: The European Commission approved Opdivo (nivolumab) plus AVD chemotherapy as the first immunotherapy-based regimen in the EU for newly diagnosed advanced classical Hodgkin lymphoma in patients aged 12+—a meaningful step for treatment options. Space Health Research: Nevis launched the Caribbean’s first space life sciences experiment, developed with the University of Zurich and CSA Switzerland and Liechtenstein, to study how gravity changes affect human immune cells and gene expression. Local Wellness Tech: Fi expanded AI-powered GPS pet wearables to 38 countries, including Switzerland and Liechtenstein, pairing health insights with real-time tracking for pet owners on the move. Travel Health Practicalities: A UK travel warning highlights that without a GHIC card, travellers may miss state-provided medical treatment abroad at local cost, so applying before travel is key.

Pharma Investment Surge: Roche and Novartis are driving a major Swiss push into the US, with $27B already invested after a tariff deal cut duties on Swiss goods from 39% to 15%—and Liechtenstein included via the customs setup. Cancer Care Update: The European Commission approved Opdivo (nivolumab) plus AVD as the first immunotherapy-based regimen in the EU for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents (12+). Space Health Research: Nevis launched the Caribbean’s first space life sciences experiment, studying how microgravity and hypergravity affect human immune cells—work tied to the University of Zurich and CSA Switzerland & Liechtenstein. Pet Health Tech: Fi expanded its AI GPS pet wearables and connectivity to 38 countries, including Switzerland and Liechtenstein, aiming to deliver health insights while traveling. Travel Health Access: UK travellers are urged to get a free GHIC card before trips to access state healthcare abroad at local cost, alongside travel insurance. Sports Governance & Money: FIS president Johan Eliasch says centralising commercial rights is boosting revenues and could add over €100M in extra profits over four years.

Space & Health Research: Nevis launched the Caribbean’s first space life sciences experiment on May 31, 2026, sending human immune cells into microgravity and hypergravity to study gene expression and cellular function—an effort built with the University of Zurich and the Centre for Space and Aviation Switzerland and Liechtenstein (including Liechtenstein). Cancer Care: The European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD chemotherapy as the first immunotherapy-based regimen in the EU for newly diagnosed advanced classical Hodgkin lymphoma in patients aged 12+ (stage III/IV). Travel Health Access: UK travellers are being urged to get a free GHIC card before trips, so they can access state-provided care abroad at free or local cost if needed. EU Visa Rules: 11 EU countries are pushing for tighter, more unified visa issuance rules for Russian citizens amid rising Schengen tourist permits. Pet Health Tech: Fi expanded its AI GPS pet wearables and connectivity to 38 countries, including Switzerland and Liechtenstein, aiming to help owners track health and location while traveling.

Visa Policy Pressure: 11 EU countries are urging the European Commission to tighten visa rules for Russian citizens, citing rising tourist and multiple-entry permits amid the war in Ukraine, with France, Italy and Spain taking the biggest share. Local Charity & Health Support: Two men are cycling the EuroVelo 15 Rhine route through Switzerland, Liechtenstein, Austria, Germany, France and the Netherlands to raise funds for a bereavement suite for baby-loss families at Southmead Hospital. Cancer Care Update: The European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD as the first immunotherapy-based regimen in the EU for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents (12+). Travel Health Access: UK travel guidance highlights that missing a GHIC card can mean higher out-of-pocket costs for state healthcare abroad, so travellers should apply before departure (GHIC doesn’t replace travel insurance). Pet Health Tech: Fi expanded its AI-powered GPS pet wearables and connectivity to 38 countries, including coverage for Switzerland, Norway and Liechtenstein. Drug Approval: CinnaGen became the first Iranian pharma firm to get EU approval for its osteoporosis medicine Zandoriah (teriparatide).

Visa Policy & Public Health Travel Risk: 11 EU countries are urging the European Commission to tighten visa rules for Russian citizens, citing rising tourist permits and fears that loopholes let more visitors reach Europe despite the war in Ukraine. Local Charity & Bereavement Care: Two men are cycling along the Rhine route through Switzerland, Liechtenstein, Austria, Germany, France and the Netherlands to raise funds for a dedicated baby-loss bereavement suite at Southmead Hospital. Cancer Treatment Access: The European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD as the first immunotherapy-based regimen in the EU for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents (12+). Pet Health Tech in the Region: Fi expanded AI-powered GPS pet wearables and connectivity to 38 countries, including coverage for Switzerland and Liechtenstein, aiming to help owners track health and behavior while traveling. Travel Costs & Healthcare Coverage: UK guidance highlights that travellers without a GHIC may miss state-provided medical treatment abroad, urging people to apply before travel (and still keep travel insurance). Medication Innovation: CinnaGen received EU approval for its osteoporosis drug teriparatide (Zandoriah), marking a first for an Iranian pharma company.

Charity Cycling for Baby Loss in Liechtenstein Region: Two men will ride the EuroVelo 15 Rhine Cycle Route from June 12, camping across Switzerland, Liechtenstein, Austria, Germany, France and the Netherlands to raise funds for Freddie’s Yellow Rose, aiming to build a dedicated bereavement suite at Southmead Hospital. EU Drug Approvals: CinnaGen became the first Iranian pharma firm to win European Commission approval for its osteoporosis medicine Zandoriah (teriparatide). Cancer Care in Europe: The European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD as the first immunotherapy-based regimen in the EU for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents (12+). Pet Health Tech in the Region: Fi expanded its AI-powered GPS pet wearables to 38 countries, including coverage for Switzerland, Norway and Liechtenstein, with behavior insights aimed at spotting health changes. Heat and Health Risks: A Europe-wide spring heat wave has shattered temperature records and is linked to multiple deaths, with warnings that more may follow. Local Sports Leadership (Liechtenstein connection): FIS president Johan Eliasch defended commercial-rights centralisation ahead of a June 11 re-election vote, with Liechtenstein’s Alexander Ospelt among candidates.

EU Drug Approvals: CinnaGen became the first Iranian pharma to win European Commission approval for its osteoporosis medicine Zandoriah (teriparatide), following EMA CHMP positive opinions and strict EU GMP checks. Cancer Care in Europe: The European Commission also approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD as the first immunotherapy-based regimen in the EU for newly diagnosed advanced classical Hodgkin lymphoma in patients aged 12+. Health Tech in the Region: Fi expanded its AI-powered GPS pet wearables to 38 countries, adding coverage across parts of North America and Europe and including Switzerland, Norway, and Liechtenstein. Heat & Safety: A deadly spring heat wave across Europe has shattered temperature records and is linked to multiple deaths, with warnings that more incidents may follow. Travel Health Access (UK): UK guidance highlights that travellers should apply for a free GHIC card before trips to help access state healthcare abroad, but it doesn’t replace travel insurance. Local Relevance: For Liechtenstein readers, the big health angle is EU approvals and regional access for new therapies and health-related tech.

Travel health access: UK travellers are being urged to get a GHIC before Europe trips, warning that without it you may have to pay local costs for state medical care. The card is free, replaces the EHIC after Brexit, and doesn’t replace travel insurance (no private care, repatriation, or disruption costs). Cancer care in Europe: The EU has approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD as the first immunotherapy-based regimen for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents (12+). CLL treatment update: AbbVie says the EU expanded VENCLYXTO (venetoclax) labeling to include fixed-duration combinations with acalabrutinib (± obinutuzumab) and with ibrutinib for first-line CLL, covering EU plus Iceland, Norway, and Liechtenstein. Transplant milestone: Hansa Biopharma reports strong one-year outcomes for Idefrix (imlifidase) after HLA-incompatible kidney transplants, with 90% graft failure-free survival in a European post-approval study. Heat and safety: A deadly spring heat wave across Europe has shattered temperature records and is linked to multiple deaths, including in the UK. Local relevance (Liechtenstein): Fi’s AI GPS pet wearable network now covers Switzerland, Norway, Liechtenstein, Iceland and more countries, expanding health insights for pets on the move.

New Cancer Treatment in Europe: The European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD for adults and adolescents (12+) with previously untreated advanced classical Hodgkin lymphoma, marking the first immunotherapy-based regimen for newly diagnosed advanced cases in the EU. CLL Therapy Update: AbbVie received an expanded EU label for VENCLYXTO (venetoclax), adding fixed-duration combinations with acalabrutinib (with/without obinutuzumab) and with ibrutinib for previously untreated chronic lymphocytic leukemia—covering EU plus Iceland, Norway, and Liechtenstein. Transplant Milestone: Hansa Biopharma reported strong one-year outcomes for Idefirix (imlifidase) in highly sensitised patients after HLA-incompatible kidney transplants, with 90% graft failure-free survival at one year and 98% patient survival. Heat & Health Risk: A deadly spring heat wave across Europe shattered temperature records and has already been linked to multiple deaths, underscoring urgent heat-safety needs. Pet Health Tech in the Region: Fi expanded AI-powered GPS pet wearables to 38 countries, including Switzerland, Norway, and Liechtenstein, offering owners health insights and tracking while traveling.